CF STORM a ground-breaking trial to assess management of CF patients daily healthcare routines
CF STORM is a ground-breaking trial to find out if people receiving Kaftrio can safely start to reduce the number of treatments they have to manage as part of their daily healthcare routine.
The CF STORM Study is funded by a £1.5m grant from the National Institute for Health Technology Assessment (HTA) Programme (ref: 131889) and is being led by Professor Kevin Southern at Alder Hey Children's NHS Foundation Trust.
CF STORM, one of the first trials of its kind, will look at whether it is safe to stop so-called mucoactive nebulisers (DNase (dornase alfa) and hypertonic saline) once eligible people with CF are established on Kaftrio.
This could save people valuable time each day that is currently spent prepping, carrying out and cleaning nebulisers, which would have a positive impact on quality of life.
If people chose to give up their nebs without a trial like CF STORM, there would be no quantified evidence for clinicians to refer to and confidently advise their patients in the future.
More Information and details can be found on the official CF Storm Website